ストックスクリーナーアプリを入手
44.50
0.80%
-0.36
アフターアワーズ：
44.50
前日終値:
$44.86
開ける：
$44.91
24時間の取引高:
991.34K
Relative Volume:
0.54
時価総額：
$3.09B
収益：
$18.09M
当期純損益:
$-208.87M
株価収益率:
-12.67
EPS:
-3.5125
ネットキャッシュフロー:
$-178.15M
1週間 パフォーマンス:
-8.66%
1か月 パフォーマンス:
+1.88%
6か月 パフォーマンス:
+392.26%
1年 パフォーマンス:
+150.99%
1日の値動き範囲:
$43.90
$45.16
1週間の範囲:
$43.90
$50.97
52週間の値動き範囲:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Compare QURE vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
44.50 | 3.39B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | アップグレード | Mizuho | Neutral → Outperform |
| 2026-03-09 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | ダウングレード | Mizuho | Outperform → Neutral |
| 2026-03-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-28 | 開始されました | Barclays | Equal Weight |
| 2025-11-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-04-01 | 再開されました | Chardan Capital Markets | Buy |
| 2024-12-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-02-29 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-17 | アップグレード | UBS | Neutral → Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-01 | アップグレード | Mizuho | Neutral → Buy |
| 2021-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-09 | 開始されました | Jefferies | Buy |
| 2020-11-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-08-25 | 開始されました | Raymond James | Strong Buy |
| 2020-07-31 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-06-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 開始されました | Cowen | Outperform |
| 2019-12-03 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Outperform |
| 2019-10-11 | 開始されました | Stifel | Buy |
| 2019-09-25 | 開始されました | Bernstein | Outperform |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-07-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-07-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Uniqure Nv (QURE) 最新ニュース
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players - NeurologyLive
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy - AD HOC NEWS
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - Yahoo Finance
uniQure Submits BLA and MAA for AMT-130 Gene Therapy in Huntington's Disease - BioPharm International
QURE Submits Application for Gene Therapy for Huntington's Disease - theglobeandmail.com
QURE Reinstated by William Blair -- Rating Set to Outperform - GuruFocus
Why is Uniqure NV stock gaining today? - Investing.com
uniQure seeks FDA accelerated nod for gene therapy (QURE) - Seeking Alpha
uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says - Benzinga
uniQure seeks US approval for Huntington's gene therapy after FDA reversal - Reuters
Why is Uniqure NV stock gaining today? By Investing.com - Investing.com Canada
QURE Looks 505.1% Overvalued on GF Value™ - GuruFocus
UniQure Submits BLA for AMT-130 in Huntington's Disease - marketscreener.com
uniQure submits BLA to FDA and MAA to MHRA for AMT-130 in Huntington’s disease - TradingView
uniQure Announces Submission of Biologics License - GlobeNewswire
Uniqure (QURE) Financials FY2025: Revenue $16.1M, Net Loss $199.0M | Income Statement & Balance Sheet - Stock Titan
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report? - Yahoo Finance
Price to sales forward of uniQure N.V. – NASDAQ:QURE - TradingView
RTW INVESTMENTS, LP Buys uniQure NV (QURE) -- Shares Look 531% O - GuruFocus
uniQure N.V. - Reuters
Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE - MarketBeat
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure (QURE) Advances 3.31% as Gene Therapy Optimism ReturnsDividend Growth Stocks - Vinanet
Responsive Playbooks and the QURE Inflection - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure - Stock Titan
RTW Investments (QURE) discloses 3.94M-share beneficial stake in uniQure N.V. - Stock Titan
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71 - Moomoo
uniQure (QURE) Q2 2026 Earnings Call Transcript - AOL.com
Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE - MarketBeat
Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE - MarketBeat
Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path - simplywall.st
Uniqure NV (QURE) Stock News Today - TradingKey
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: Exploring A 53.35% Potential Upside In Gene Therapy - DirectorsTalk Interviews
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
QURE|Uniqure NV|Price:44.206|Chg%:-0.034 - TradingKey
Weekly Recap: AMT-130 readout and Wells Fargo raises QURE target to $75 - TradingView
Militia Capital Management LLC Invests $1.54 Million in uniQure N.V. $QURE - MarketBeat
uniQure N.V. (QURE) Stock Analysis: Assessing Upside Potential and Analyst Confidence in Biotech Innovator - DirectorsTalk Interviews
uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course (NASDAQ:QURE) - Seeking Alpha
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - TradingView
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - Moomoo
Uniqure NV earnings missed by $0.38, revenue topped estimates - Investing.com Nigeria
uniQure N.V. 2026: Revenue $5.84M, EPS ($1.22) — 10-Q Summary - TradingView
UniQure: Q2 Earnings Snapshot - 10tv.com
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update - GlobeNewswire
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Uniqure Nv (QURE) 財務データ
収益
当期純利益
現金流量
EPS
Uniqure Nv (QURE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Jul 02 '26 |
Sale |
45.16 |
21,082 |
952,051 |
519,227 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
5.59 |
10,000 |
55,900 |
178,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Sale |
46.42 |
30,000 |
1,392,600 |
148,235 |
| Kaye Jack | Director |
Jun 30 '26 |
Option Exercise |
23.44 |
21,167 |
496,230 |
43,056 |
| Kaye Jack | Director |
Jun 30 '26 |
Sale |
46.44 |
21,167 |
983,030 |
25,996 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):